UBS Group’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $23.4M | Sell |
4,630,590
-939,192
| -17% | -$4.75M | ﹤0.01% | 1728 |
|
|
2025
Q1 | $29.5M | Buy |
5,569,782
+2,565,137
| +85% | +$13.6M | 0.01% | 1528 |
|
|
2024
Q4 | $20.3M | Buy |
3,004,645
+2,204,785
| +276% | +$14.9M | ﹤0.01% | 1744 |
|
|
2024
Q3 | $5.27M | Sell |
799,860
-849,190
| -51% | -$5.6M | ﹤0.01% | 2222 |
|
|
2024
Q2 | $12.4M | Buy |
1,649,050
+976,619
| +145% | +$7.32M | ﹤0.01% | 1493 |
|
|
2024
Q1 | $6.7M | Sell |
672,431
-19,480
| -3% | -$194K | ﹤0.01% | 1916 |
|
|
2023
Q4 | $6.82M | Buy |
691,911
+349,232
| +102% | +$3.44M | ﹤0.01% | 1728 |
|
|
2023
Q3 | $2.62M | Buy |
342,679
+173,954
| +103% | +$1.33M | ﹤0.01% | 2342 |
|
|
2023
Q2 | $1.26M | Sell |
168,725
-210
| -0.1% | -$1.57K | ﹤0.01% | 3098 |
|
|
2023
Q1 | $1.13M | Sell |
168,935
-192,960
| -53% | -$1.29M | ﹤0.01% | 3089 |
|
|
2022
Q4 | $2.79M | Buy |
361,895
+343,430
| +1,860% | +$2.65M | ﹤0.01% | 2287 |
|
|
2022
Q3 | $196K | Buy |
18,465
+13,479
| +270% | +$143K | ﹤0.01% | 4076 |
|
|
2022
Q2 | $41K | Sell |
4,986
-1,941
| -28% | -$16K | ﹤0.01% | 5058 |
|
|
2022
Q1 | $49K | Sell |
6,927
-252,295
| -97% | -$1.78M | ﹤0.01% | 5500 |
|
|
2021
Q4 | $4.44M | Buy |
259,222
+188,079
| +264% | +$3.22M | ﹤0.01% | 2203 |
|
|
2021
Q3 | $1.64M | Buy |
71,143
+70,443
| +10,063% | +$1.62M | ﹤0.01% | 2889 |
|
|
2021
Q2 | $26K | Buy |
+700
| New | +$26K | ﹤0.01% | 5992 |
|